Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04894994 · ClinicalTrials.gov registry record · Phase 2
FLX475 in Combination With Ipilimumab in Advanced Melanoma
A Phase 2 study, sponsored by RAPT Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04894994 is a Phase 2 study that was terminated before completion, run by RAPT Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT04894994, a Phase 2 study, was terminated before completion, sponsored by RAPT Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.
Interventions
- DRUG Ipilimumab
- DRUG FLX475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2022-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04894994
The ClinicalTrials.gov registry entry for NCT04894994 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RAPT Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT04894994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04894994 about?
NCT04894994 is a clinical study titled "FLX475 in Combination With Ipilimumab in Advanced Melanoma". This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The stud...
What is the current status of trial NCT04894994?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-09-03. Estimated completion is 2022-09-13.
What interventions are being tested in trial NCT04894994?
The interventions under investigation include: Ipilimumab (DRUG), FLX475 (DRUG).
Who is sponsoring clinical trial NCT04894994?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.